Q3 Earnings Forecast for AVDL Issued By Leerink Partnrs

Key Points

• Leerink Partners has significantly lowered its Q3 2025 EPS forecast for Avadel Pharmaceuticals to ($0.11), down from a previous estimate of $0.05.
• The stock has received mixed ratings from analysts, with UBS Group issuing a buy rating and Weiss Ratings maintaining a sell rating.
• As of now, Avadel Pharmaceuticals has a market cap of $1.38 billion, with its stock trading at $14.21, reflecting a 1.8% decrease.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Avadel Pharmaceuticals in a research report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.11) for the quarter, down from their previous estimate of $0.05. The consensus estimate for Avadel Pharmaceuticals' current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals' Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.25 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.70 EPS.

A number of other research analysts also recently weighed in on AVDL. Weiss Ratings reissued a "sell (e+)" rating on shares of Avadel Pharmaceuticals in a research report on Wednesday. Wells Fargo & Company raised shares of Avadel Pharmaceuticals to a "hold" rating in a research report on Wednesday, September 3rd. UBS Group increased their target price on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Zacks Research downgraded shares of Avadel Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Finally, Lifesci Capital raised shares of Avadel Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $20.86.

Avadel Pharmaceuticals Stock Down 1.8%

Avadel Pharmaceuticals stock opened at $14.21 on Thursday. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $16.66. The firm has a 50 day moving average price of $14.44 and a 200-day moving average price of $10.89. The company has a market capitalization of $1.38 billion, a P/E ratio of -473.67 and a beta of 1.46.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.02 by $0.08. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. The firm had revenue of $68.13 million during the quarter, compared to analyst estimates of $60.28 million. During the same quarter last year, the business posted ($0.14) EPS. The company's revenue for the quarter was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVDL. California State Teachers Retirement System boosted its holdings in Avadel Pharmaceuticals by 10.2% in the 4th quarter. California State Teachers Retirement System now owns 81,448 shares of the company's stock valued at $856,000 after purchasing an additional 7,544 shares during the period. Rhumbline Advisers boosted its holdings in Avadel Pharmaceuticals by 2.3% in the 1st quarter. Rhumbline Advisers now owns 127,027 shares of the company's stock valued at $995,000 after purchasing an additional 2,890 shares during the period. Wealth Effects LLC boosted its holdings in Avadel Pharmaceuticals by 1.1% in the 1st quarter. Wealth Effects LLC now owns 2,369,122 shares of the company's stock valued at $18,550,000 after purchasing an additional 24,992 shares during the period. Investors Asset Management of Georgia Inc. GA ADV boosted its holdings in Avadel Pharmaceuticals by 16.4% in the 1st quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 139,975 shares of the company's stock valued at $1,096,000 after purchasing an additional 19,700 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in Avadel Pharmaceuticals by 4.0% in the 1st quarter. Bank of New York Mellon Corp now owns 234,120 shares of the company's stock valued at $1,833,000 after purchasing an additional 9,025 shares during the period. 69.19% of the stock is owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.